Solabegron
- Generic Name
- Solabegron
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23ClN2O3
- CAS Number
- 252920-94-8
- Unique Ingredient Identifier
- 55P6YH9O6N
- Background
Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.
- Indication
Investigated for use/treatment in diabetes mellitus type 2, irritable bowel syndrome (IBS), and urinary incontinence.
A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers
Phase 1
Completed
- Conditions
- Irritable Bowel Syndrome (IBS)
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00401479
- Locations
- 🇺🇸
GSK Investigational Site, Rochester, Minnesota, United States
A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)
Phase 2
Completed
- Conditions
- Irritable Bowel Syndrome (IBS)
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT00394186
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms
Phase 2
Completed
- Conditions
- Overactive Bladder
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT00343486
- Locations
- 🇨🇳
GSK Investigational Site, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath